1. Bayer Pharmaceuticals Corporation (9 from 70 patents)

2. Bayer Corporation (5 from 1,008 patents)

3. Bayer Healthcare LLC (5 from 780 patents)

4. Bayer Intellectual Property Gmbh (3 from 721 patents)

5. Other (1 from 832,680 patents)

1. RE46856 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

2. 8859572 - Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis

3. 8841330 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

4. 8466283 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

5. 8124630 - ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

6. 7928239 - Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

7. 7897623 - ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors

8. 7625915 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

9. 7528255 - Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors

10. 7517880 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

11. 7371763 - Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas

12. 7351834 - ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

13. 7329670 - Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

14. 7235576 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

15. 7109196 - 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders